ArticleFrontiers in neurology
Validation and clinical utility of OMGRate and MG-QOL15 in evaluating symptoms and quality of life in Chinese patients with ocular myasthenia gravis.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the value of the OMGRate and MG-QOL 15 in assessing quality of life (QoL) before and after treatment in ocular myasthenia gravis (OMG) and to validate the applicability of OMGRate in the Chinese OMG population. Methods: This prospective observational cohort study was conducted via questionnaire among patients diagnosed with OMG at our hospital between November 2022 and January 2024. Patient outcomes were assessed at pre-treatment (baseline), 1, 3, and 6 months post-treatment. Efficacy was assessed using the OMGRate and O-QMGS, while the MG-QOL15 was used to evaluate the QoL of OMG patients. Results: Our study included 52 patients with OMG. Age of onset and first Symptoms significantly impacted patients' QoL ( Conclusion: The OMGRate was validated as an effective method for severity assessment in Chinese OMG patients. OMG significantly impairs patients' QoL, whereas standardised treatment not only effectively alleviates clinical symptoms but also concurrently improves quality of life, revealing good consistency between symptomatic improvement and patient-reported outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.